FibroGen’s (FGEN) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of FibroGen (NASDAQ:FGEN) in a report released on Tuesday,Benzinga reports. The brokerage currently has a $10.00 price target on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for FibroGen’s Q1 2025 earnings at $0.04 EPS, Q2 2025 earnings at $0.05 EPS, Q3 2025 earnings at ($0.15) EPS, Q4 2025 earnings at ($0.17) EPS, FY2025 earnings at ($0.31) EPS and FY2026 earnings at ($0.69) EPS.

Separately, StockNews.com started coverage on shares of FibroGen in a research report on Friday, March 14th. They set a “hold” rating on the stock.

FibroGen Stock Performance

Shares of FGEN stock opened at $0.34 on Tuesday. FibroGen has a one year low of $0.18 and a one year high of $2.80. The company’s 50-day simple moving average is $0.49 and its 200-day simple moving average is $0.43. The stock has a market capitalization of $33.91 million, a price-to-earnings ratio of -0.27 and a beta of 0.82.

FibroGen (NASDAQ:FGEN) last issued its quarterly earnings results on Monday, March 17th. The biopharmaceutical company reported ($0.08) EPS for the quarter, hitting the consensus estimate of ($0.08). The company had revenue of $3.14 million for the quarter, compared to the consensus estimate of $24.91 million. As a group, research analysts forecast that FibroGen will post -0.8 EPS for the current year.

Institutional Investors Weigh In On FibroGen

Several institutional investors and hedge funds have recently bought and sold shares of FGEN. JPMorgan Chase & Co. raised its stake in FibroGen by 430.7% during the third quarter. JPMorgan Chase & Co. now owns 1,673,555 shares of the biopharmaceutical company’s stock worth $668,000 after acquiring an additional 1,358,194 shares during the period. Renaissance Technologies LLC raised its stake in FibroGen by 80.4% during the fourth quarter. Renaissance Technologies LLC now owns 1,358,712 shares of the biopharmaceutical company’s stock worth $719,000 after acquiring an additional 605,572 shares during the period. Mackenzie Financial Corp raised its stake in FibroGen by 416.6% during the fourth quarter. Mackenzie Financial Corp now owns 546,959 shares of the biopharmaceutical company’s stock worth $290,000 after acquiring an additional 441,083 shares during the period. Squarepoint Ops LLC acquired a new stake in FibroGen during the fourth quarter worth about $205,000. Finally, Two Sigma Advisers LP raised its stake in FibroGen by 18.3% during the fourth quarter. Two Sigma Advisers LP now owns 878,400 shares of the biopharmaceutical company’s stock worth $465,000 after acquiring an additional 135,600 shares during the period. Institutional investors and hedge funds own 72.71% of the company’s stock.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.